Abstract
We have demonstrated the effects of estrogen on modulation of ATP-sensitive K+ channels; however, the subcellular location of these channels is unknown. The purpose of the present study was to investigate the role of the sarcolemmal and mitochondrial ATP-sensitive K+ channels in a canine model of myocardial infarction after stimulation with 17β-estradiol. Anesthetized dogs were subjected to 60 min of the left anterior descending coronary artery occlusion followed by 3 h of reperfusion. Infarct size was markedly reduced in estradiol-treated dogs compared with controls (14 ± 6 versus 42 ± 6%, P < 0.0001), indicating the effective dose of estradiol administrated. Pretreatment with the mitochondrial ATP-sensitive K+ channel antagonist 5-hydroxydecanoate completely abolished estradiol-induced cardioprotection. The sarcolemmal ATP-sensitive K+ channel antagonist 1-15-12-(5-chloro-o-anisamido)ethyl-methoxyphenyl)sulfonyl-3-methylthiourea (HMR 1098) did not significantly attenuate estradiol-induced infarct size limitation. In addition, estradiol administration significantly reduced the incidence and duration of reperfusion-induced ventricular tachycardia and ventricular fibrillation. Although 5-hydroxydecanoate alone caused no significant effect on the incidence of reperfusion arrhythmias in the presence or absence of estradiol, the administration of HMR 1098 abolished estrogen-induced improvement of reperfusion arrhythmias. Pretreatment with the estrogen-receptor antagonist faslodex (ICI 182,780) did not alter estrogen-induced infarct-limiting and antiarrhythmic effects. These results demonstrate that estrogen is cardioprotective against infarct sizes and fatal reperfusion arrhythmias by different ATP-sensitive K+channels for an estrogen receptor-independent mechanism. The infarct size-limiting and antiarrhythmic effects of estrogen were abolished by 5-hydroxydecanoate and HMR 1098, suggesting that the effects may result from activation of the mitochondrial and sarcolemmal ATP-sensitive K+ channels, respectively.
Footnotes
-
This work was supported by Grant NSC89-2314-B002-186 from the National Science Council, (Taiwan, Republic of China) and by Grant NTUH89S1026 from National Taiwan University Hospital.
- Abbreviations:
- IP
- ischemic preconditioning
- mit-KATP
- mitochondrial KATP
- sar-KATP
- sarcolemmal KATP
- VF
- ventricular fibrillation
- VT
- ventricular tachycardia
- HMR 1098
- 1-15-12-(5-chloro-o-anisamido)ethyl-methoxyphenyl)sufonyl-3-methylthiourea
- ICI 182,780
- faslodex
- Received June 4, 2001.
- Accepted January 11, 2002.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|